Drug intelligence / Profile preview

PS-003

Development stage: Preclinical
Lead developer: Pharmasaga
Modality: Small Molecules
Administration: Oral

Overview

PS-003 is an investigational small molecule therapeutic being developed by Pharmasaga for the treatment of cancer. Currently in the preclinical stage of development, the drug is formulated as an oral tablet. While specific molecular targets and mechanisms of action have not been publicly disclosed by the developer, it represents part of Pharmasaga's pipeline alongside metabolic disease candidates like PS-001 and PS-002.

Beyond the preview

Go deeper on PS-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PS-003.

Explore the full profile